ADHD Med Trials Often Miss the Mark
Clinical relevance: Persistent Adderall shortages and rising diagnoses highlight the mismatch between randomized controlled trials and real-world ADHD treatment. A Swedish study revealed that more than 53 percent of nearly 190,000 ADHD patients would not qualify for traditional RCTs. Ineligible patients faced significantly higher risks of adverse outcomes, including psychiatric hospitalizations and specialist care for mental health and substance use issues. RCTs often exclude patients with comorbid conditions, creating a gap between trial findings and real-world treatment needs.
Other Articles in this Edition
ADHD Incidence Trends Fluctuated from 2016 to 2023 in Adults, Adolescents
FDA bans Red No. 3, artificial coloring used in beverages, candy and other foods
ADHD Med Trials Often Miss the Mark
Music can improve focus for people with ADHD—here’s what to listen for
In Atopic Dermatitis, Dupilumab Use Linked to Less Sleep, Psychiatric Disorders
High-fat diet linked to impulsive behaviors and brain changes
Connecting Biology to Behavior: Inside the ADHD Brain
How to build a more inclusive workplace for those with ADHD, autism or PTSD: Ask HR